Plasma levels of dopamine metabolite correlate with mismatch negativity in patients with schizophrenia.
dopamine
event-related potential
homovanillic acid
mismatch negativity
schizophrenia
Journal
Psychiatry and clinical neurosciences
ISSN: 1440-1819
Titre abrégé: Psychiatry Clin Neurosci
Pays: Australia
ID NLM: 9513551
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
19
07
2019
revised:
20
12
2019
accepted:
17
01
2020
pubmed:
30
1
2020
medline:
1
6
2021
entrez:
30
1
2020
Statut:
ppublish
Résumé
Mismatch negativity (MMN) deficit is one of the most robust and replicable findings in schizophrenia, and primarily reflects deficient functioning of the N-methyl-D-aspartate (NMDA) receptor system. Although the dopamine receptor is known not to modulate MMN over the short term, it is unclear whether the dopamine system affects MMN in the long term. We explored correlations between MMN and levels of plasma dopamine and serotonin metabolites in 18 patients with schizophrenia psychiatrically evaluated with the Positive and Negative Syndrome Scale (PANSS). A significant negative correlation exists between MMN amplitude and plasma levels of dopamine metabolites. Plasma serotonin metabolite levels were not correlated with MMN. The PANSS total score and Negative score also showed negative correlations with MMN amplitude. The usual strong therapeutic blockade of dopamine receptors applied in cases of schizophrenia may reduce MMN over the long term.
Substances chimiques
Serotonin
333DO1RDJY
Hydroxyindoleacetic Acid
54-16-0
Dopamine
VTD58H1Z2X
Homovanillic Acid
X77S6GMS36
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-293Subventions
Organisme : Grants for Research Support provided by Fukushima Medical University
Informations de copyright
© 2020 The Authors. Psychiatry and Clinical Neurosciences © 2020 Japanese Society of Psychiatry and Neurology.
Références
Huang J, Tan SP, Walsh SC et al. Working memory dysfunctions predict social problem solving skills in schizophrenia. Psychiatry Res. 2014; 220: 96-101.
Gilmour G, Dix S, Fellini L et al. NMDA receptors, cognition and schizophrenia: Testing the validity of the NMDA receptor hypofunction hypothesis. Neuropharmacology 2012; 62: 1401-1412.
Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 1991; 148: 1301-1308.
Kantrowitz JT, Javitt DC. Thinking glutamatergically: Changing concepts of schizophrenia based upon changing neurochemical models. Clin. Schizophr. Relat. Psychoses 2010; 4: 189-200.
Krystal JH, Karper LP, Seibyl JP et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 1994; 51: 199-214.
Lahti AC, Koffel B, LaPorte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 1995; 13: 9-19.
Malhotra AK, Pinals DA, Adler CM et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology 1997; 17: 141-150.
Näätänen R. Attention and Brain Function. Erlbaum, Hillsdale, NJ, 1992.
Schröger E. On the detection of auditory deviations: A pre-attentive activation model. Psychophysiology 1997; 34: 245-257.
Salisbury DF, Kuroki N, Kasai K, Shenton ME, McCarley RW. Progressive and interrelated functional and structural evidence of post-onset brain reduction in schizophrenia. Arch. Gen. Psychiatry 2007; 64: 521-529.
Umbricht D, Koller R, Vollenweider FX, Schmid L. Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers. Biol. Psychiatry 2002; 51: 400-406.
Umbricht D, Schmid L, Koller R, Vollenweider FX, Hell D, Javitt DC. Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: Implications for models of cognitive deficits in schizophrenia. Arch. Gen. Psychiatry 2000; 57: 1139-1147.
Kahkonen S, Ahveninen J, Pekkonen E et al. Dopamine modulates involuntary attention shifting and reorienting: An electromagnetic study. Clin. Neurophysiol. 2002; 113: 1894-1902.
Leung S, Croft RJ, Baldeweg T, Nathan PJ. Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects. Psychopharmacology 2007; 194: 443-451.
Pekkone E, Hirvonen J, Ahveninen J et al. Memory-based comparison process not attenuated by haloperidol: A combined MEG and EEG study. Neuroreport 2002; 13: 177-181.
Horton J, Millar A, Labelle A, Knott VJ. MMN responsivity to manipulations of frequency and duration deviants in chronic, clozapine-treated schizophrenia patients. Schizophr. Res. 2011; 126: 202-211.
Zhou Z, Zhu H, Chen L. Effect of aripiprazole on mismatch negativity (MMN) in schizophrenia. PLoS One 2013; 8: e52186.
Maas JW, Hattox SE, Greene NM, Landis DH. Estimates of dopamine and serotonin synthesis by the awake human brain. J. Neurochem. 1980; 34: 1547-1549.
Miura I, Takeuchi S, Katsumi A et al. Effects of aripiprazole and the Taq1A polymorphism in the dopamine D2 receptor gene on the clinical response and plasma monoamine metabolites level during the acute phase of schizophrenia. J. Clin. Psychopharmacol. 2012; 32: 106-109.
Alfredsson G, Wiesel FA. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology 1990; 101: 324-331.
Markianos M, Botsis A, Arvanitis Y. Biogenic amine metabolites in plasma of drug-naive schizophrenic patients: Associations with symptomatology. Biol. Psychiatry 1992; 32: 288-292.
Inagaki A, Inada T. Dose equivalence of psychotropic drugs. Part XXI: Dose equivalence of novel antipsychotics: Blonanserin. Jpn J. Clin. Psychopharmacol. 2008; 11: 887-890.
Soda E, Miura I, Hoshino H et al. Impacts of age on plasma monoamine metabolite concentrations in a large cohort of healthy individuals. Psychiatry Res. 2014; 220: 639-645.
Korostenskaja M, Kicic D, Kahkonen S. The effect of methylphenidate on auditory information processing in healthy volunteers: A combined EEG/MEG study. Psychopharmacology 2008; 197: 475-486.
Leung S, Croft RJ, Guille V et al. Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants. Psychopharmacology 2010; 208: 233-244.
Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. DARPP-32: An integrator of neurotransmission. Annu. Rev. Pharmacol. Toxicol. 2004; 44: 269-296.
Greengard P, Allen PB, Nairn AC. Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade. Neuron 1999; 23: 435-447.
Li SC, Passow S, Nietfeld W et al. Dopamine modulates attentional control of auditory perception: DARPP-32 (PPP1R1B) genotype effects on behavior and cortical evoked potentials. Neuropsychologia 2013; 51: 1649-1661.
Driesen NR, McCarthy G, Bhagwagar Z et al. The impact of NMDA receptor blockade on human working memory-related prefrontal function and connectivity. Neuropsychopharmacology 2013; 38: 2613-2622.
Lett TA, Voineskos AN, Kennedy JL, Levine B, Daskalakis ZJ. Treating working memory deficits in schizophrenia: A review of the neurobiology. Biol. Psychiatry 2014; 75: 361-370.
Moghaddam B. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology 2004; 174: 39-44.
Friedman JI, Temporini H, Davis KL. Pharmacologic strategies for augmenting cognitive performance in schizophrenia. Biol. Psychiatry 1999; 45: 1-16.
Goldman-Rakic PS, Selemon LD. Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophr. Bull. 1997; 23: 437-458.
Lee SH, Sung K, Lee KS, Moon E, Kim CG. Mismatch negativity is a stronger indicator of functional outcomes than neurocognition or theory of mind in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014; 48: 213-219.
Miyanishi T, Sumiyoshi T, Higuchi Y, Seo T, Suzuki M. Loreta current source density for duration mismatch negativity and neuropsychological assessment in early schizophrenia. PLoS One 2013; 8: e61152.
Fisher DJ, Grant B, Smith DM, Borracci G, Labelle A, Knott VJ. Effects of auditory hallucinations on the mismatch negativity (MMN) in schizophrenia as measured by a modified ‘optimal’ multi-feature paradigm. Int. J. Psychophysiol. 2011; 81: 245-251.
Grzella I, Muller BW, Oades RD et al. Novelty-elicited mismatch negativity in patients with schizophrenia on admission and discharge. J. Psychiatry Neurosci. 2001; 26: 235-246.
Youn T, Park HJ, Kim JJ, Kim MS, Kwon JS. Altered hemispheric asymmetry and positive symptoms in schizophrenia: Equivalent current dipole of auditory mismatch negativity. Schizophr. Res. 2003; 59: 253-260.
Catts SV, Shelley AM, Ward PB et al. Brain potential evidence for an auditory sensory memory deficit in schizophrenia. Am. J. Psychiatry 1995; 152: 213-219.
Javitt DC, Shelley A, Ritter W. Associated deficits in mismatch negativity generation and tone matching in schizophrenia. Clin. Neurophysiol. 2000; 111: 1733-1737.
Salisbury DF, Shenton ME, Griggs CB, Bonner-Jackson A, McCarley RW. Mismatch negativity in chronic schizophrenia and first-episode schizophrenia. Arch Gen Psychiatry 2002; 59: 686-694.
Light GA, Swerdlow NR, Thomas ML et al. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr. Res. 2015; 163: 63-72.
Fulham WR, Michie PT, Ward PB et al. Mismatch negativity in recent-onset and chronic schizophrenia: A current source density analysis. PLoS One 2014; 9: e100221.
Thomas ML, Green MF, Hellemann G et al. Modeling deficits from early auditory information processing to psychosocial functioning in schizophrenia. JAMA Psychiatry 2017; 74: 37-46.
Baldeweg T, Hirsch SR. Mismatch negativity indexes illness-specific impairments of cortical plasticity in schizophrenia: A comparison with bipolar disorder and Alzheimer's disease. Int. J. Psychophysiol. 2015; 95: 145-155.
Devrim-Uçok M, Keskin-Ergen HY, Uçok A. Mismatch negativity at acute and post-acute phases of first-episode schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 2008; 258: 179-185.
Dulude L, Labelle A, Knott VJ. Acute nicotine alteration of sensory memory impairment in smokers with schizophrenia. J. Clin. Psychopharmacol. 2010; 30: 541-548.
Perez VB, Woods SW, Roach BJ et al. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: Forecasting psychosis risk with mismatch negativity. Biol. Psychiatry 2014; 75: 459-469.
Erickson MA, Albrecht M, Ruffle A, Fleming L, Corlett P, Gold J. No association between symptom severity and MMN impairment in schizophrenia: A meta-analytic approach. Schizophr. Res. Cogn. 2017; 9: 13-17.
Umbricht DS, Bates JA, Lieberman JA, Kane JM, Javitt DC. Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. Biol. Psychiatry 2006; 59: 762-772.
Giard MH, Perrin F, Pernier J, Bouchet P. Brain generators implicated in the processing of auditory stimulus deviance: A topographic event-related potential study. Psychophysiology 1990; 27: 627-640.
Vollenweider FX, Vontobel P, Hell D, Leenders KL. 5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man: A PET study with [11C]raclopride. Neuropsychopharmacology 1999; 20: 424-433.
Aghajanian GK, Marek GJ. Serotonin model of schizophrenia: Emerging role of glutamate mechanisms. Brain Res. Rev. 2000; 31: 302-312.
Aghajanian GK, Marek GJ. Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells. Neuropharmacology 1997; 36: 589-599.
Wienberg M, Glenthoj BY, Jensen KS, Oranje B. A single high dose of escitalopram increases mismatch negativity without affecting processing negativity or P300 amplitude in healthy volunteers. J. Psychopharmacol. 2010; 24: 1183-1192.
Kähkönen S, Mäkinen V, Jääskeläinen IP, Pennanen S, Liesivuori J, Ahveninen J. Serotonergic modulation of mismatch negativity. Psychiatry Res. 2005; 138: 61-74.
Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM. Serotonin: A review. J. Vet. Pharmacol. Ther. 2008; 31: 187-199.